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Assessing DNA methylation in the developing
human intestinal epithelium: potential link to
inflammatory bowel disease
J Kraiczy1, KNayak1, A Ross1, T Raine2, TNMak1,MGasparetto1, E Cario3, V Rakyan4, RHeuschkel5 and
M Zilbauer1,5,6
DNAmethylation is oneof themajor epigeneticmechanisms implicated in regulating cellulardevelopment andcell-type-
specific gene expression. Here we performed simultaneous genome-wide DNA methylation and gene expression
analysis onpurified intestinal epithelial cells derived fromhuman fetal gut, healthy pediatric biopsies, andchildren newly
diagnosed with inflammatory bowel disease (IBD). Results were validated using pyrosequencing, real-time PCR, and
immunostaining. The functional impact of DNA methylation changes on gene expression was assessed by employing
in-vitro assays in intestinal cell lines. DNAmethylation analyses allowed identification of 214 genes forwhich expression
is regulated via DNA methylation, i.e. regulatory differentially methylated regions (rDMRs). Pathway and functional
analysis of rDMRs suggested a critical role for DNA methylation in regulating gene expression and functional
development of the human intestinal epithelium.Moreover, analysis performedon intestinal epitheliumof children newly
diagnosed with IBD revealed alterations in DNA methylation within genomic loci, which were found to overlap
significantly with those undergoing methylation changes during intestinal development. Our study provides novel
insights into the physiological role of DNA methylation in regulating functional maturation of the human intestinal
epithelium. Moreover, we provide data linking developmentally acquired alterations in the DNA methylation profile to
changes seen in pediatric IBD.
INTRODUCTION
The intestinal mucosa represents the largest area of the human
body in direct contact with the exterior environment. In
addition to its involvement in digestion and nutrient absorp-
tion, the intestinal epithelium has a key role in regulating
barrier function and immune homeostasis in the gastrointest-
inal (GI) tract.1 In mammals, development of a fully
differentiated and functioning intestinal epithelium is a
complex process, beginning in utero with formation of a
stratified epithelial cell layer, derived from the visceral
endoderm.2 Although shortly before birth the final crypt-
villus architecture and all major cell subsets (e.g., absorptive
enterocytes, Paneth cells, goblet cells, and enteroendocrine
cells) are present, the epithelium remains functionally imma-
ture.3 At birth, a dramatic change occurs as the epithelium is
colonized by the microbiota. Indeed, bacterial colonization,
combined with exposure to an increasing variety of food
antigens, is required for the normal postnatal functional
development of the intestinal epithelium.4 This early life
interaction between the host epithelial cells and the environ-
ment has been shown to be particularly important in
establishing mucosal barrier and immune functions such as
the ability of the epithelium to sense microbial stimuli and
mount an appropriate response.5 Importantly, incomplete
development or acquired impairment of intestinal epithelial
cell/barrier function has been implicated in pathogenesis of
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several intestinal diseases, including necrotizing enterocolitis
and inflammatory bowel disease (IBD).5–7 Although the
phenotypic and functional changes in the intestinal epithelium
during human embryonic and early postnatal development
have been well described, the underlying regulatory molecular
mechanisms remain incompletely understood.
Epigenetic mechanisms are known to regulate gene expres-
sion and cellular function in the absence of changes to the
underlying DNA sequence. DNA methylation is among the
most extensively studied epigenetic modifications and occurs at
the 50 position of the pyrimidine ring of cytosines, primarily in
the context of a CpG dinucleotide sequence.8 CpGmethylation
is thought to regulate gene expression through its effect on
chromatin state, as well as accessibility of transcription factor-
binding sites.9 In principle, increased methylation of CpGs
(hypermethylation), in particular when located within pro-
moter regions or in close proximity of the transcription start
site, is associated with silencing of the respective gene, whereas
hypomethylation has the opposite effect.10
DNA methylation has been shown to have a critical role in
regulating lineage commitment of embryonic stem cells,
cellular differentiation, as well as cell-type-specific gene
expression of fully differentiated cell subsets.11,12,13 However,
to date, only limited information is available on the potential
role of DNA methylation in regulating gene expression and
cellular function in the human intestinal epithelium during
embryonic and early life development. In addition, it has been
proposed that epigenetic modifications may provide the
mechanistic link between development, environmental change
and altered gene expression.14Hence, they potentially represent
a key biological mechanism mediating the rapid increase in
complex conditions, including IBD, over the last century, in the
absence of major changes to the human genome.15,16
Here we studied DNA methylation changes in the human
intestinal epithelium during embryonic and postnatal develop-
ment, with an aim to elucidate their functional role in regulating
gene expression as well as their potential implication for IBD
pathogenesis.
RESULTS
DNA methylation profiles of purified fetal and pediatric
intestinal epithelium
First we performed genome-wideDNAmethylation analysis on
a discovery sample set (n¼ 12) of purified intestinal epithelial
cells obtained from human fetal gut (i.e., proximal and distal)
and pediatric biopsies derived from terminal ileum and two
colonic segments (ascending colon and sigmoid colon). We
performed multidimensional scaling analysis (MDS), which
visualizes the level of similarity of individual samples, taking all
of the B470,000 data points present on the array into
consideration. As shown in Figure 1a, the first dimension
(i.e., x axis), separates samples according to their developmental
age (i.e., fetal vs. pediatric), whereas the second dimension
(i.e., y axis) divides samples by gut segment. These findingswere
further confirmed by performing unsupervised hierarchical
clustering analyses, demonstrating major methylation
differences between fetal and pediatric intestinal epithelium
(Figure 1b).
Next we categorized each CpG position into either
methylated, partially methylated, or unmethylated, according
to their respective methylation value. Differences in the
distribution of probes were most obvious by developmental
age and, to a lesser extent, by gut location, but were particularly
pronounced in ‘‘unmethylated’’ and ‘‘partially methylated’’
categories (Figure 1c). Moreover, as demonstrated in
Figure 1c, unmethylated probes were primarily located
within CpG islands and enriched in promoter regions
(Figure 1c and Supplementary Figure S1 online).
Identification of rDMRs
In order to investigate the role of DNA methylation in
regulating gene expression in the intestinal epithelium, we
performed simultaneous genome-wide expression profiling on
purified cell samples. Similar to the observed differences in
DNA methylation profiles, MDS analysis of gene expression
data separated epithelial samples according to developmental
age and gut location (Figure 2a).
Given this similar clustering pattern, we next aimed to
identify genes for which expression might be primarily
regulated through DNA methylation during the process of
development from the immature fetal to the fully differentiated
pediatric epithelium. We therefore performed comparative
DNA methylation and gene expression analysis between the
combined fetal (i.e., proximal and distal gut) and pediatric
(i.e., terminal ileum, ascending colon, and sigmoid colon)
sample set. As summarized in Figure 2b, we filtered out highly
significant differentially methylated positions (DMPs), which
were then grouped into differentially methylated regions
(DMRs) by combining probes located in close proximity
(see Methods). DMRs found to be associated with one unique
gene, which also displayed significant differences in gene
expression, were classed as potential regulatory DMRs
(rDMRs). A very strict significant cut-off as well as log-fold
change threshold was chosen in order to identify genes, for
which DNA methylation changes are most likely to have a role
in regulating gene expression. In total, we identified 259
rDMRs, whichwere associated with 214 genes (Supplementary
Table S1). Methylation and gene expression profiles of selected
rDMRs are displayed in Figure 2c, illustrating the robust
absolute DNA methylation differences ranging up to 60% and
associated changes in gene expression. Moreover, compared
with all identified DMRs (i.e., including those in genes not
associated with changed expression), rDMRs were more
frequently found to overlap with annotated transcription
start site, further highlighting the likely functional impact of
DNA methylation changes on gene expression in identified
genomic regions (Figure 2d).
Identified genes containing rDMRs are enriched for
pathways associated with immune function, GI
development, and intestinal disease
In order to gain insight into which biological functions might
be epigenetically regulated in the intestinal epithelium, we
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performed pathway analysis on all 214 genes containing
rDMRs. We found that top gene networks and physiological
functions include ‘‘Embryonic development,’’ ‘‘Tissue mor-
phology/development,’’ and ‘‘Digestive system development
and function’’ (Figure 3a). In addition, disease-related
networks were significantly enriched for ‘‘Gastrointestinal
disease’’ and ‘‘Immunological diseases.’’ Figure 3b illustrates
one of the major networks ‘‘Embryonic development, Tissue
Morphology, Immunological Disease,’’ which contained a
number of key genes known to be involved in intestinal
epithelial immune defence such as polymeric immunoglobulin
receptor (PIGR) and trefoil factor 3 (TFF3), as well asmolecules
implicated in epithelial differentiation via the regulation of the
Wnt and/or PI3K/Akt signaling pathway (e.g., TCF7L1 and
WIF1).17
rDMRs validated in an independent sample cohort
In order to validate findings derived from genome-wide array
data, we used pyrosequencing and real-time PCR to examine
DNA methylation and gene expression on a selection of
identified rDMRs in a second sample cohort (n¼ 9–12 per
group). Given the association of genes containing rDMRs with
immune function and related disease development, we selected
genes based on their roles in the innate immune defence system
(i.e.,MUC2, TLR3, PIGR, and IL6R) or in epigenetic regulation
(i.e., TET1 (tet methylcytosine dioxygenase 1)). As shown in
Figure 4a, results confirmed highly significant methylation
differences (450%) between fetal and pediatric intestinal
epithelium. Similarly, differences in gene expression were also
confirmed as highly significant, reaching a log-fold scale in the
majority of selected rDMR-associated genes (Figure 4b). An
inverse relationship between gene expression and promoter
DNA methylation was identified for all loci (Figure 4c). We
also observed that with increasing age, hypomethylation of
innate immune response genes occured, associated with
upregulation in their expression. In contrast, the gene encoding
TET1, an enzyme involved in DNA demethylation, gained
methylation through development, which was associated with
downregulation of gene expression. Previous reports have
shown that unlike in upstream promoter regions, intragenic
Figure 1 Genome-wide DNAmethylation profiles of purified human fetal (n¼ 6 from 3 donors) and pediatric intestinal epithelium (n¼ 6 from 2 donors).
(a) Multidimensional scaling analysis (MDS) plot displaying the overall DNA methylation profiles considering all probes. The first dimension (x axis)
separates fetal from pediatric epithelial samples. The second dimension distinguishes epithelium according to gut location, separating proximal, small
bowel from distal, large bowel. (b) Unsupervised hierarchical clustering confirms developmental age as the main factor separating samples into two
groups, i.e., fetal andpediatric. (c)Distribution of loci according to theirmethylation status; ‘‘unmethylated,’’ ‘‘partiallymethylated,’’ and ‘‘fullymethylated’’.
The average number of loci in each group is plotted. Each bar is further sub-divided, indicating location of probes in relation to CpG islands. FDG, fetal
distal gut (n¼ 3); FPG, fetal proximal gut (n¼ 3); PAC, pediatric ascending colon (n¼ 2) ; PSC, pediatric sigmoid colon (n¼ 2); PTI, pediatric terminal
ileum (n¼ 2).
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Figure 2 ‘Genome-wide gene expression analysis was performed on simultaneously extracted RNA from purified human intestinal epithelium.
(a)Multidimensional scalinganalysis (MDS)plot displayingclusteringof samplesaccording todevelopmental age in the first dimension,whereas the second
dimension separates epithelial cells according to gut segment. (b) Overview of the algorithm used to identify regulatory differentially methylated regions
(rDMRs) by integrating both genome-wideDNA and gene expression data. In total, we identified 259 rDMRs associatedwith 214 genes. (c) Summary plots
of selected rDMRs displaying DNA methylation and gene expression of PIGR (polymeric immunoglobulin receptor), TLR3, TET1 (tet methylcytosine
dioxygenase 1),MUC2, and IL6R. The top panel indicates the level of DNAmethylation across the DMRaccording to themethylation b-value (y axis). Each
point represents one sample and the line indicating the average methylation value. Additional panels indicate relation of DMR to the reference human
genome. Inset displays correspondinggeneexpressionplottedas log2 averageexpressionof eachsample. (d)Distributionof all DMRs (i.e., includingDMRs
for which associated genes do not display expression changes) vs. rDMRs according to their genomic location. rDMRs are found more frequently to be
located either fully inside or overlapping with transcription start site (TSS). DMP, differentially methylated position; FDG, fetal distal gut (n¼ 3); FPG, fetal
proximal gut (n¼ 3); PAC, pediatric ascending colon (n¼ 3); PSC, pediatric sigmoid colon (n¼ 3); PTI, pediatric terminal ileum (n¼ 3).
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hypermethylation is associated with an increase in gene
expression.18 Consistent with these reports, we found that
in the gene body of TLR3, hypermethylation correlated with
increased gene expression (Supplementary Figure S2).
Subsequent immunostaining for PIGR,MUC2, and TLR3 on
fetal and pediatric samples suggests that real-time PCR data are
reflective of protein levels. Specifically, in contrast to absent or
low protein expression in the distal fetal gut epithelium, all
proteins were highly expressed in the intestinal epithelium of
pediatric colonic samples (Figure 5).
Functional relevance of DNAmethylation changes on gene
transcription
Next, we aimed to demonstrate a direct impact of changes in
DNA methylation on gene expression by employing two
frequently used in-vitro models. First, we treated intestinal
epithelial cell line (Caco-2) with a DNA methyltransferase
inhibitor for 24 to 48 h. As demonstrated in Figure 6a, DNA
methylation of candidate genes displayed a significant
reduction, accompanied by a corresponding increase in
gene expression. Next, we tested the functional relevance of
DNA methylation on gene transcription in a locus-specific
manner by cloning promoter regions of selected genes into a
luciferase vector containing a CpG-free backbone.19 As shown
in Figure 6b, in-vitro methylation of the PIGR and TLR3
promoter-containing plasmid led to a significant reduction of
luciferase signal compared with the unmethylated construct.
Basic luciferase activity of the unmethylated MUC2 promoter
plasmid was found to be very low and no further reduction was
observed following in-vitro methylation (Figure 6b).
Figure 3 Ingenuity pathway analysis (IPA) performed on identified regulatory differentially methylated region (rDMR)-containing genes. (a) Bar plot
displaying scores of the top five networks and physiological functions, indicating the number of involved genes in each group and the enrichmentP-value.
(b) Major network ‘‘Embryonic development, tissue morphology, immunological disease’’. Graph shows gene symbols with color coding of differentially
methylated and expressed genes. Red color indicates gene expression upregulated, green color represents gene expression downregulated in pediatric
epithelium (compared with fetal). Numbers below symbols indicate the expression logFC (pediatric vs. fetal). Non-colored symbols indicate genes not in
the input data but involved in the network shown. Molecule relationships were simplified using the ‘‘IPA Path Designer’’ tool.
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Altered DNA methylation in the intestinal epithelium of
children with IBD
The above data suggest that methylation changes at key
immune regulators controls their expression during the
development of healthy intestinal epithelium and alterations
may be involved in GI and immunological diseases pathogen-
esis. Therefore, we next investigated whether aberrant epige-
netic modifications are found in children with a confirmed
diagnosis of IBD. We performed genome-wide DNA methyla-
tion profiling of purified colonic intestinal epithelium obtained
from an additional cohort of children newly diagnosed with
IBD (treatment naive), as well as matched healthy controls. As
shown in Figure 7a, unsupervised hierarchical clustering
analysis of DNA methylation profiles revealed clear separation
into two groups, one containing all healthy control samples and
five IBD samples, with the second cluster containing only
samples obtained from children with IBD. Importantly, sub-
clustering observed within IBD patients could not be solely
attributed to the presence of intestinal inflammation
(Figure 7a). MDS analyses confirmed these findings, with
the first dimension separating control samples from IBD
samples (Figure 7b), whereas the second dimension divides
samples according to their gut location (i.e., sigmoid vs.
ascending colon).
IBD-specific intestinal epithelial methylation profiles
significantly overlap with probes undergoing methylation
changes during GI development
Next, we aimed to investigate whether the observed IBD-
specific alterations in DNA methylation could primarily occur
in loci that are dynamically methylated during intestinal
epithelial development. We therefore performed differential
methylation analysis comparing IBD samples with control
samples. Using the same stringent significance cut-off as before
(i.e., adjusted Po.01 and log-fold change 4±1.5), we
identified a total of 233 DMPs (Supplementary Table S2).
Interestingly, a statistically highly significant proportion of
these IBD-specific DMPs overlapped with DMPs from the fetal
vs. pediatric sample data set comparison (Figures 7c,
Po8.5e 32). This was also the case when lowering the
Figure 4 Validation of DNA methylation and gene expression differences between fetal and pediatric epithelial cells in a second sample cohort using
pyrosequencing and reverse transcription–PCR. (a) CpG methylation in promoter regions of PIGR (polymeric immunoglobulin receptor),MUC2, TLR3,
IL6R, and TET1 (tet methylcytosine dioxygenase 1). Data are presented as the average and s.d. of absolute DNA methylation values in %. Two-way
analysis of variance, *Po0.05, ***Po0.005, ****Po0.001, n¼ 6–16 (minimum of four donors in each group). (b) Gene expression was assessed in
parallel displaying significant differences between fetal and pediatric epithelial samples. Mann–Whitney test, *Po0.05, *** Po0.005, n¼7–12.
(c) Correlation between DNAmethylation across the assessed region (average of three to eight CpGs) and respective mRNA expression was assessed
by calculating the Pearson’s correlation coefficient (r). Each dot represents one sample.
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significance cut-off by including all DMPs with an adjusted
Po.01 regardless of log-fold change (Figure 7c). Moreover, a
number of the previously highlighted genes (e.g., PIGR and
MUC2) containing identified rDMRs were found to display
distinct methylation differences in IBD patients compared with
controls, both in array data of the identified rDMR, as well as
using locus-specific pyrosequencing (Figure 7d,e).
DISCUSSION
Epigenetic mechanisms are emerging as key factors in
regulating the fundamental biological processes driving cellular
differentiation as well as cell-type-specific function.8,20
Evidence is also accumulating that epigenetic mechanisms
mediate the effects of a changing environment on mammalian
embryonic and early-life development, something that has been
linked to the increase in incidence of complex, multifactorial
diseases including IBD.14,21 In this study we investigated the
role of DNA methylation in regulating intestinal epithelial
function during GI development and assessed whether
alterations may have an impact on IBD pathogenesis.
We first generated and analyzed genome-wide DNA
methylation profiles derived from healthy fetal and pediatric
epithelium. Results revealed distinct differences between fetal
and pediatric samples, providing a first indication that dynamic
changes in DNAmethylation are involved in the maturation of
the developing gut epithelium. We then went on to identify
genomic regions for which an association was observed
between DNA methylation and gene expression (rDMRs).
Using a stringent significance cut-off, we identified a total of
214 genes containing one or more rDMRs. Given the relatively
small sample size of our discovery cohort, we further validated a
selected subset of rDMRs in a second sample cohort,
confirming highly significant absolute changes in methylation
of up to 60%. Furthermore, these methylation changes are
observed consistently across multiple CpG sites. Together with
corresponding changes in gene expression, as well as the strong
inverse correlation between methylation and gene expression,
we suggest that expression of those genes is highly likely to be
regulated by DNA methylation.
Despite a large body of existing evidence supporting a role for
DNA methylation in regulating gene transcription, an associa-
tion between changes within a given gene does not prove these
changes are functionally related.8 However, demonstrating a
causative relationship between an epigeneticmark and a change
in gene expression remains one of the major challenges in the
field. We were able to demonstrate that treatment of an
intestinal epithelial cell line with DNA methyltransferase
inhibitors led to reduced levels of DNA methylation and an
associated increase in gene expression of all tested genes.
Moreover, in-vitro methylation of promoter regions in a
CpG-free luciferase reporter plasmid led to a significant
reduction in promoter activity of TLR3 and PIGR. These
results strongly suggest that DNAmethylation has a functional
role in regulating gene expression at our identified rDMRs.
Based on our findings so far, we hypothesized that these
genomic regions might represent important epigenetic
regulators in gut development and postnatal functional
maturation of the intestinal epithelium. Specifically, we
speculated that network analysis on identified rDMRs could
provide further insight into what aspects of the intestinal
epithelial functional development might be, at least in part,
epigenetically regulated. Indeed, pathway analysis performed
on all rDMRs revealed a significant enrichment for networks
involved in embryonic, tissue, and GI development, suggesting
an essential role for DNA methylation in regulating these
fundamental biological processes. In fact, performing a detailed
Figure 5 Protein expression of polymeric immunoglobulin receptor (PIGR), MUC2, and TLR3 was assessed by immunofluorescent staining in fetal
distal gut (upper panel) and pediatric ascending colon (lower panel). Expression of all three proteins was found to be either absent or low in fetal gut
samples and highly abundant in pediatric colonic epithelium. Fetal gut sections display the presence of a stratified epithelial layer with a complete lack of
crypt villus axis. Protein expression pattern corresponds with mRNA levels of the respective genes and is confined to the intestinal epithelium. Staining
was performed on tissue samples obtained from three donors in each group, representative images are shown. White bar represents 50 mm. Blue, 4’,6-
diamidino-2-phenylindole-counterstained nuclei; red, PIgR; yellow, Muc2; green, Tlr3.
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literature research revealed substantial evidence that supports
the role of a large proportion of rDMR-containing genes in
intestinal epithelial-specific functions (Supplementary Table
S3). Examples include genes involved in innate immune/
antimicrobial defence such as mucin (MUC2), pattern
recognition receptors (TLR3 and TLR4) fucosyltransferases
(FUT3 and FUT6), PIGR, and TFF3, as well as genes involved
in antigen presentation such asHLA class II genes (e.g.,HLA-C,
HLA-DMA, HLA-DMB, HLA-DPB1, and HLA-DRA).
Importantly, many of these genes have been implicated in
the pathogenesis of IBD including TLR3 and TLR4,22MUC2,23
PIGR,24 TFF3,25 and HLA-DRA.26 Moreover, the majority of
genes contributing to intestinal epithelial defencewere found to
be hypermethylated, with expression either absent or at low
levels in fetal samples. During the transition to a fully developed
pediatric epithelium, these genes became hypomethylated and
hence actively expressed.
In addition to genes associated with immune function,
rDMRs were also enriched within genes known to have key
roles in intestinal development. DNA methylation has been
shown to regulate cellular differentiation through the activation
of lineage-specific genes at the appropriate time during cellular
development.20 We identified several rDMR-containing genes
known to be involved in driving cellular development
and differentiation. These include TCF7L1 and WIF1, both
recognized regulators of the Wnt signaling pathway as well as
Figure 6 In-vitro assays demonstrate the direct impact of DNA methylation on transcription of regulatory differentially methylated region (rDMR)-
containing genes. (a) Caco-2 cells were treated with DNA methyltransferase (DNMT) inhibitor (10 mM 5-Azacytidine (AzaC) for 24 h and for 48 h or 5mM
5-Azadeoxycytidine (AzadC) for 24 h. DNAmethylation of the polymeric immunoglobulin receptor (PIGR),MUC2, and TLR3 promoter was assessed by
pyrosequencing. Reduced levels of CpG methylation with a corresponding increase in mRNA expression was observed. Data are displayed as
meanþ s.d. of three independent experiments performed in duplicates. Two-way analysis of variance, post test; Sidak, *Po0.05, **Po0.005,
***Po0.001 vs. dimethylsulfoxide (DMSO) vehicle control. (b) Promoter regions of MUC2, TLR3, and PIGR were cloned into a CpG-free luciferase
reporter plasmid. In-vitromethylation of TLR3 andPIGR promoter plasmids led to a significant reduction in luciferase signal comparedwithmock-treated
unmethylated plasmids. Basic luciferase activity of MUC2 promoter containing plasmid was found to be low in Caco-2 cells and no further reduction was
observed following in-vitro methylation. Basic, CpG-free plasmid with no promoter. Renilla-luciferase served as control to correct for transfection
efficiency.Meanþ s.d. of three independent experiments performed in duplicates;Student’s unpaired t-test, two tailed,n¼3per condition. ***Po0.0001,
**Po0.005, Po0.57 (NS, not significant).
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Figure 7 Alteration of DNA methylation in colonic epithelial cells of children diagnosed with inflammatory bowel disease (IBD) occurs at sites
undergoing dynamic methylation changes during gastrointestinal (GI) development. (a) Hierarchical clustering of genome-wide DNA methylation
profiles of colonic intestinal epithelial cells obtained from children newly diagnosed with IBD (treatment naive) and matched healthy controls
(n¼ 5 patients per group and 2 biopsy samples per patient). The presence of mucosal inflammation is indicated. (b) Multidimensional scaling analysis
(MDS) analysis confirmsmethylation differences present in themajority of IBD samples comparedwith healthy controls. (c) Venndiagramshowing the
overlap of significant differentially methylated positions (DMPs) derived from the comparison of fetal vs. pediatric samples in the discovery cohort and
newly diagnosed IBD epithelium vs. healthy controls. Up to 40%ofCpGs displaying significant alterations in IBDepitheliumwere also found to undergo
significant DNA methylation changes during the transition from fetal to pediatric epithelium. Overlaps between DMPs were found to be highly
significant (hypergeometric enrichment test Po8.5E 32). (d) Alterations of DNA methylation in the intestinal epithelium of children newly
diagnosed with IBDwere found to be present in regulatory differentially methylated regions (rDMRs) ofMUC2 and polymeric immunoglobulin receptor
(PIGR). Methylation b-values derived from array data (IBD sample cohort) are plotted in genomic context. (e) DNA methylation of respective DMRs
assessed using pyrosequencing. Meanþ s.d., n¼ 5 individuals per group (i.e., 5 healthy controls, 5 CD, and 5 UC). Analyses were performed in
duplicates on two biopsy samples per patient, multiple t-test, post test: Holm–Sidak, *Po0.05 vs. control. CD, Crohn’s Disease; Ctrl, Control;
UC, ulcerative colitits.
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olfactomedin4 (OLFM4).27,28 Although the experimental
design of our study does not allow differentiating between
epigenetic modification as a cause or consequence to changes
in gene expression, our findings support and further
extend existing evidence that DNA methylation plays
a critical role in the development of the human intestinal
epithelium.
Increasing evidence suggests that epigenetic mechanisms
including DNA methylation might have a crucial role in IBD
pathogenesis.15,16 Although limited studies have been per-
formed in human mucosal tissue, results have been suppor-
tive.29–31 However, given the fact that DNA methylation
profiles are highly cell-type specific, analysis on mixed cell
tissue samples (e.g., mucosal biopsies), in particular in the
context of an inflammatory condition, carry a high risk of
yielding results confounded by cellular composition.32 Here we
generated genome-wide DNA methylation profiles of highly
purified intestinal epithelium obtained from a treatment-naive
pediatric patient cohort, as well as matched healthy controls.
Unsupervised clustering and MDS analysis of these methyla-
tion profiles clearly separated out a subset of IBD samples with
all controls grouping closely together. Importantly, this
clustering pattern appeared not to be entirely due to the
presence or absence of inflammation, implying the possibility
of an IBD-specific intestinal epithelial DNA methylation
signature in these patients.
A developmental origin of health and disease has
been proposed by many as a plausible framework in which
epigenetic mechanisms mediate environmental effects during
vulnerable stages of development, ultimately causing disease
when exposed to appropriate later triggers (second/multiple hit
theory).33 We hypothesized that genomic areas displaying
differential methylation between fetal and pediatric samples
may represent potential susceptibility regions, in
which alteration of DNA methylation status might predispose
to disease. We therefore tested for an overlap between highly
significant DMPs identified between fetal and pediatric
samples, and DMPs derived from comparison of children
with IBD and healthy controls.We observed a highly significant
overlap, with up to 40% of CpGs differentially methylated in
children with IBD, among those undergoing significant
changes in DNA methylation between the first trimester of
pregnancy and childhood. These findings suggest that
epigenetic alterations during critical periods of human
fetal and postnatal development, potentially mediated
via exposure to specific environmental factors, could predis-
pose and ultimately cause development of chronic intestinal
inflammation.
In summary, our study provides novel insight into the
role of DNA methylation in regulating human intestinal
epithelial development and function. The striking overlap
between genomic loci undergoing significant DNA
methylation changes during GI development with those
observed in children diagnosed with IBD supports a devel-
opmental origin of IBD hypothesis, mediated through
epigenetic mechanisms.
METHODS
Human fetal gut and intestinal biopsy samples. Colonoscopy was
performed by experienced pediatric gastroenterologists, who collected
three additional mucosal biopsies each from the terminal ileum,
ascending colon, and sigmoid colon. Biopsies were taken within 2–
3 cm of those taken for routine histological assessment, which was
performed by experienced consultant GI histopathologists. Diagnosis
of Crohn’s disease and ulcerative colitis was based on standard criteria
using clinical, radiological, endoscopic, and histopathological findings
in accordance with established criteria. Children with macroscopically
and histologically normal mucosa, with no subsequent evidence of any
underlying GI pathology, served as a healthy control group. All studies
were conducted with informed patient and/or carer consent as
appropriate, and with full ethical approval (REC-12/EE/0482). Fetal
intestine was obtained with full ethical approval (REC-96/085)
following informed consent following elective terminations at 8–12
week gestation, carried out for reasons other than maternal physical
health or fetal disease. Fetal gut was dissected and divided into the
proximal and distal sections at the reliably identifiable ileocecal
junction. Sample and patient details are provided as Supplementary
Material.
Purification of intestinal epithelial cells. Purification of intestinal
epithelium from pediatric mucosal biopsies and fetal gut samples was
performed using enzyme digestion, followed by magnetic bead sorting
as described previously.32 This protocol yields highly purified epi-
thelial cell fractions, which was routinely confirmed by assessing
lymphocyte contamination using flow cytometry. Details and a
representative analysis are provided as Supplementary Material
(Supplementary Figure S3).
Genome-wide DNAmethylation and gene expression arrays. DNA
and RNA were extracted simultaneously from the same sample using
the AllPrep DNA/RNAmini kit (Qiagen, Hilden, Germany) following
the manufacturer’s instructions.11 Genome-wide DNA methylation
was assessed using bisulfite-converted DNA on the Illumina Infinium
HumanMethylation450 BeadChip platform (Illumina, Cambridge,
UK). Gene expression was analyzed using AffymetrixHumanGene ST
1.0 Array (Affymetrix UK Ltd, High Wycombe, UK). Both methods
have been described in more detail previously.11 Data have been
deposited in the ArrayExpress database under the following accession
numbers: E-MTAB-3703 (Illumina K450 DNA methylation arrays
discovery cohort), -E-MTAB-3704 (Affymetrix gene expression arrays
discovery cohort), and E-MTAB-3709 (Illumina K450 DNA
methylation arrays paediatric IBD and control cohort).
RT and real-time PCR. One hundred to 500 ng of RNA were reverse
transcribed using QuantiTect Reverse Transcription Kit
(Qiagen). Complementary DNA corresponding to 5 ng RNA was
used for real-time PCR using QuantiFast SYBR Green PCR
Master Mix (Qiagen) on the 7500 Fast real-time PCR system, 7500
software v2.0.6 (Applied Biosciences by Thermo Fisher Scientific,
Paisley, UK). Relative quantitation was calculated using the DDCt
method following normalization against GAPDH.34
Bisulfite-conversion and pyrosequencing. Extracted DNA was
bisulfite treated using EZ DNAmethylation Gold kit (Zymo Research,
Irvine, CA) according to the manufacturer’s instructions. Locus-
specific PCR amplification and quantification of DNA methylation
levels were performed on bisulfite-converted DNA using Pyromark
Gold reagents on a Pyromark Q24 (Qiagen) pyrosequencing system as
described previously.32 Further details are provided as Supplementary
Material.
Immunohistochemistry. Tissue specimens were fixed in 4%
formaldehyde in phosphate-buffered saline, stepwise dehydrated,
and embedded in paraffin. Paraffin sections (4mM) were rehydrated
by subsequent incubation with xylene and descending concentrations
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of ethanol. Heat-induced antigen retrieval was performed for 20min in
a conventional steamer. Nonspecific binding of antibodies was
prevented by blocking with 10% normal goat serum and 1% bovi-
neserum albumin in phosphate-buffered saline. Primary antibodies
were incubated overnight at 4 1C. After washing, secondary antibodies
were incubated for 1 h at room temperature before washing and
mounting. Details of antibodies are provided as Supplementary
Material. Images were taken using a SP5 Leica confocal microscope
(Leica Microsystems, Milton Keynes, UK).
DNA methyltransferase inhibitor treatment. Caco-2 cells were
treated with 10 mM 5-Azacytidine or 5 mM 5-Azadeoxycytidine for
24–48 h, whereas dimethylsulfoxide served as vehicle control.
Following incubation periods, cells were lysed before simultaneous
DNA and RNA extraction.
DNA methylation-specific Luciferase reporter gene assays.
Genomic promoter regions of interest were cloned from human DNA
into a CpG-free luciferase reporter vector as described previously.19
Following, plasmids were in vitro methylated by incubation with
recombinant CpG methyltransferase M.SssI (New England Biolabs,
Ipswich, MA) in the provided buffer and supplemented with 3mM S-
adenosylmethionine at 37 1C for 4 h. Control plasmids were processed
in the same way without addition of M.SssI. Following enzyme heat
inactivation at 65 1C for 20min, plasmid DNA was isolated using a
PCR purification kit (Qiagen) and quantified by spectrophotometer.
Caco-2 were transfected at 60% confluence for 24 h using Lipo-
fectamine with Plus Reagent (Life Technologies by Thermo Fisher
Scientific) and 100 ng reporter vector per well (96-well plate).
Differences in transfection efficiency and cell density were corrected
for by co-transfection with 3 ng Renilla luciferase reporter vector
pRL-CMV E226V (Promega, Madison, WI). Cells were given 6 h of
recovery in normal medium before addition of passive lysis buffer.
Reporter gene activity was measured with dual luciferase assay
reagents (Promega) in a GloMax 96 Microplate Luminomer
(Promega). Relative chemiluminescence is expressed as ratio of raw
reading of Firefly luciferase/Renilla luciferase, multiplied by factor 103,
to improve legibility. pCpGL-Basic (no promoter) served as negative
control and pCpGL-CMV served as positive control.
Statistical analysis. DNAmethylation analysis were performed using
R software for statistical analysis and the Bioconductor packagesminfi
and limma were used for normalization and the majority of
downstream analysis including generation of MDS plots and hier-
archical clustering analysis.35,36 Affymetrix gene expression array
analysis was performed according to established standard protocols as
published previously.11 Further details can be found in the
Supplementary Methods.
Data were further analyzed through the use of Qiagen’s Ingenuity
Pathway Analysis (www.qiagen.com/ingenuity).
Statistical tests for data other than genome-wide arrays were
performed in GraphPadPrism 6 software (GraphPad Software, La
Jolla, CA). Two groupswere compared by Student unpaired, two-tailed
t-test, in case of unequal variances with Welch correction, or Mann–
Whitney rank test. Two groups in more than two conditions were
compared by two-way analysis of variance with Sidak’s correction for
multiple testing. Multiple (42) groups were compared by multiple t-
test with Holm–Sidak post test.
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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